 On the U.S. government's books, gold is worth $42.22 an ounce. That price was set in 1973. Today, gold trades around $4,500. That's a 113-to-1 gap between what the Treasury says its gold is worth… and what it's actually worth. Treasury Secretary Scott Bessent has told us what he wants to do about it. On the record, he said he intends to "monetize the asset side of the balance sheet." That's not a throwaway line. It's a signal. Because the easiest way to monetize that side of the ledger is to do one thing: Revalue the gold. With a single decision, the government could mark up its reserves by more than $1 trillion overnight. After 20 years studying gold and debt cycles, I can tell you what that kind of move really means. A government doesn't revalue its gold when things are fine. It does it when the other side of the balance sheet — the debt side — is in trouble. It's what you do when you need to signal strength to the world because the old source of strength is failing. And every other signal is already flashing:
- Oil is settling in yuan through the Iranian toll booth in Hormuz.
- The petrodollar arrangement was cracking even before the war.
- Foreign demand for Treasuries is fading.
When a shift like this comes, it doesn't arrive gradually. And when the government revalues gold to save itself, that's the moment you cannot own enough of it. But do not run out and buy bullion at these prices. Because certain miners offer far more asymmetric upside — the ones still priced as if gold were under $2,000 while it trades near all-time highs. I call them the Golden Anomaly. Go here for the four best-positioned picks before the revaluation. To your wealth, Garrett Goggin, CFA, CMT
Chief Analyst and Founder, Golden Portfolio P.S. The Treasury carries its gold at $42 an ounce and the sitting Treasury Secretary wants to "monetize the asset side." Connect those two facts and you see what's coming. Go here to see the four miners positioned ahead of it.
This Week's Exclusive Article
Insiders Are Betting Big on These 3 Healthcare StocksReported by Thomas Hughes. Published: 8/31/2026. 
Key Points
- Insiders are heavily buying speculative pharma stocks in the third quarter, signaling confidence.
- Braveheart Bio and BlossomHill Therapeutics are early-stage biopharmaceuticals with heavy insider buying, but low institutional ownership creates overhang and downside risk.
- Elanco offers a lower-risk pet and livestock health play with steady insider buying, a Moderate Buy rating, and an ongoing price recovery.
- Special Report: Moderna Doubled in One Day. This Medical Stock Could Be Next
Insiders are betting big on pharma in Q3, highlighting opportunities for speculative investors. Speculation is the key word, as these stocks carry risks alongside potentially strong rewards. The question is what is driving insiders' interest—and how large the potential gains could be. Braveheart Bio Boldly Goes Where Few Have Gone BeforeBraveheart Bio (NASDAQ: BRVE) is a late-stage biopharmaceutical company that completed its IPO earlier this year. The company's lead candidate, BHB-1893, is transitioning to Phase 3 trials following positive Phase 2 results, offering substantial upside for investors.
The therapy targets hypertrophic cardiomyopathy, a segment worth upward of $5 billion in annual sales at peak. Opportunities include disrupting established leaders while penetrating a largely underserved market. Analysts estimate that as few as 20% of eligible patients are currently treated. Insiders buying the stock include a host of C-suite executives, including the CFO and CDO, as well as numerous directors, early investors and major shareholders. Their purchases coincided with the IPO and included expanded positions at near-record prices, pushing total insider ownership above 17%. Institutional ownership remains low because venture capital and private equity firms primarily own the company. The risk is that these firms sell into any rallies, creating an overhang until market dynamics change. That is likely to happen over the coming quarters as Phase 3 trials begin, but the real catalyst—the results—is unlikely to arrive until late 2027 at the earliest. Looking ahead, the treatment is undergoing several studies, with results expected over the next two to three years to drive market sentiment, assuming the first produces a positive result. Analyst coverage is light but reflects an optimistic outlook for the stock. It currently has five ratings, with a consensus Buy rating and about 80% upside. The likely outcome is for the stock to trade sideways within its range over the next year, potentially trending lower until signs of traction emerge. While Braveheart's potential is bright, it is burning through capital and is unlikely to stop doing so within the next 12 to 18 months. 
BlossomHill Therapeutics: The Higher-Risk OptionBlossomHill Therapeutics (NASDAQ: BLSM) is a cancer-focused biopharma in a similar position to Braveheart Bio. However, while Braveheart Bio has a candidate entering late-stage trials, BlossomHill Therapeutics does not. Its three candidates are either preclinical or in early Phase 1 trials, so the company is still determining whether to proceed. As a result, it has an even longer runway to revenue and profits, although it has a larger end market. Insiders buying this stock include a similar mix of C-suite executives and directors, as well as OrbiMed Advisors. OrbiMed Advisors is a global investment firm focused on health care, with more than $20 billion under management. It acts as a lead investor, investing across the life cycle and helping companies grow into their potential. Analyst coverage and institutional ownership highlight the stock's risks. Institutions hold a token 5% of the shares, while no analysts covering BlossomHill are currently tracked. As a result, BLSM shares are ripe for short-selling, sharp corrections and downtrends, despite the fast-track status achieved by one of its candidates. 
Elanco: Pet-Friendly Investment With a Robust Pipeline, Growth and ProfitsElanco (NYSE: ELAN) is not a traditional health care company, as it focuses on pets and livestock. The business is divided into two operating segments: Companion Animal and Livestock, providing name-brand vaccines, medicines and technology across both segments. Catalysts in 2026 include a corporate turnaround centered on a robust pipeline. Its latest launch has already achieved blockbuster status, and strength is expected to continue as new products launch. Insiders buying the stock include directors, the CFO and an executive vice president, extending a trend that has lasted for the past two years. Analysts rate it as a Moderate Buy and show modest conviction, with 13 analysts covering the stock. They have a bullish bias and see the stock rising 20% to the consensus target, highlighting its growth and profit potential. Unlike BRVE and BLSM, ELAN did not recently go public. The stock has been trading for several years and is in the midst of a price recovery. After declining in 2023 on sluggish growth and lackluster prospects, the stock bottomed in 2024, and the rebound is now gaining momentum. The consensus price target of $29 would be enough to break the stock out of consolidation and set a new high, opening the door to a larger advance over time. Elanco's biggest risks are operational, including foreign exchange changes, product launches, adoption and regulatory changes. Foreign exchange effects hit results quarterly and can swing from helpful to harmful in a single quarter. Product launches and adoption pose greater risks because they increase upfront costs and can lead to weaker-than-expected results when delayed, sluggish or disrupted by competition. 
. |
